JAYPIRCA

This brand name is authorized in Austria, France, Croatia, Ireland, Italy, Lithuania, Romania, United States

Active ingredients

The drug JAYPIRCA contains one active pharmaceutical ingredient (API):

1 Pirtobrutinib UNII JNA39I7ZVB - PIRTOBRUTINIB

Pirtobrutinib is a reversible, noncovalent inhibitor of BTK. BTK is a signalling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK as well as BTK harboring C481 mutations leading to inhibition of BTK kinase activity. Read about Pirtobrutinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
JAYPIRCA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EL05		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EL Bruton's tyrosine kinase (BTK) inhibitors
Discover more medicines within L01EL05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 67881720, 68606652
Country: IT	Agenzia del Farmaco	Identifier(s): 050942010, 050942022, 050942034, 050942046, 050942059, 050942061, 050942073, 050942085, 050942097
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098037, 1098038, 1098039, 1098040, 1098041, 1098042, 1098043, 1098044, 1098045
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69920001, W69921001
Country: US	FDA, National Drug Code	Identifier(s): 0002-6902, 0002-7026